Arterial are a breath of fresh air in the EIS/alternative asset space. The transparency of their IM’s and its supporting information is industry leading. But best of all the quality of the investment opportunities they introduce are simply exceptional. Arterial align their interests with the investor from the start to the finish and I have no hesitation to recommend them to other advisers who wish to do likewise.

NIGEL McTEAR – Founder, Signpost Financial Planning


Quantum Research and Valuation have worked with Arterial since 2013 providing in-depth research, financial analysis and valuation. Arterial’s approach to asset selection and the global strength of their team and their scientific, industry and financial expertise is outstanding. It is a pleasure to be associated with a firm that sets standards to which others should aspire to.



Hutchinson IP were recently voted “IP Innovator: Mechanical IP” firm of the year 2015 by Acquisition International Magazine. Our firm has worked with Arterial since 2014 on a number of biotech startup/investment projects. We have first-hand experience of the incredibly high standards they demand of their counterparties, and their uncompromising insistence on all aspects of due diligence for investee firms. The Arterial team are one of the best and most proactive teams I have worked with, being immensely experienced in the biotech sector, and bringing both depth and breadth of international expertise to the UK EIS market.

TOM HUTCHINSON M.Eng.(Hons), RPA, CPA, EPA, EDA – Director, Hutchinson IP


Wealthmasters have many years experience of advising our clients on alternative assets including Enterprise Investment Schemes. Throughout our time working with Arterial we have always found the quality of their EIS investee propositions to be exceptional in terms of the independent due diligence and research provided on the investment opportunity. Therefore I am confident in presenting their propositions to our clients.

JOHN WALLS DipIP PFA CeMAP MIoD – Managing Director, Wealthmasters Financial Management Ltd


I was introduced to Arterial in May 2015 with a view to raising significant capital for my life science technology business.  I found their approach exceptionally refreshing, simultaneously favouring both the business founders and the investors. This was very different to anything that I had previously come across when speaking with private equity firms.  Arterial’s support has been far reaching, in that they have been instrumental in introducing me to a number of captains of industry, some of whom are now on my board! I thoroughly recommend Arterial and their amazing team to any life science business seeking both funds and a partner committed to making their business a global success.

Dr. SABIH CHAUDHRY – Founder & CEO of  Orsus Medical Ltd


I have worked with Arterial since shortly after their launch, reviewing prospective investee companies for EIS compatibility and handling all EIS matters from initial HMRC advance assurance through to submission of forms EIS1. I am delighted to work with Arterial, and proud to be able to consider my firm to be one of their professional counterparties.

CHRISTOPHER LEE – Managing Director, Fiscability UK Limited, Former Inspector of Taxes & Senior Tax Partner, James Cowper LLP


Our firm has recommended Arterial to a number of clients. We have been very impressed with the high levels of due diligence and corporate governance which we have found to be leagues above any other UK EIS offering that we have advised upon. Arterial are an exceptional firm and we will continue to recommend them to our clients.

JAMES FERGUSON DipFA – Director of Enness Wealth, Independent Financial Adviser


Turner Parkinson’s Corporate Finance team act for a number of Arterial investee businesses. We are fully conversant with the high standards of due diligence and verification of all documents, and overall attention to detail demanded by Arterial. In particular the knowledge and global track record of their scientific team, and their unerring commitment to international standards of corporate governance to protect EIS investors is incredibly reassuring.

STEPHEN HADLOW – Partner, Turner Parkinson LLP


New Europe Advisers has worked with ACM on a number of transactions. We have found the quality of issuers introduced to us by Arterial to be exceptional. Staff always act in a professional and efficient way and we are very pleased to work with them on these transactions.

MARK OTTO – Chief Executive, New Europe Advisers Ltd


I first met the Arterial team in 2012 when they entered into negotiations with our company to explore the opportunity on investing in the company’s Biotechnology IP. We found their approach to funding for life science, their professionalism and the global reputation of their team and their determination to see a business succeed was so refreshing in comparison to numerous other VC’s we had previously approached. We have no hesitation in recommending other life science companies to work with the Arterial management team who we know will enthusiastically pursue a successful outcome.

Dr. DOUGLAS REES PhD MRSNZ – Founder, Director & CSO, AQIX Ltd